<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03806530</url>
  </required_header>
  <id_info>
    <org_study_id>DISCO_RLS_001</org_study_id>
    <nct_id>NCT03806530</nct_id>
  </id_info>
  <brief_title>DIalysis Symptom COntrol-Restless Legs Syndrome Trial</brief_title>
  <acronym>DISCO-RLS</acronym>
  <official_title>DIalysis Symptom COntrol-Restless Legs Syndrome Trial (DISCO-RLS Trial): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DISCO-RLS Trial is a randomized controlled trial to determine the safety and efficacy of
      pharmacologic therapy (ropinirole versus placebo and gabapentin versus placebo) for the
      treatment of Restless Legs Syndrome in patients with End Stage Renal Disease requiring
      hemodialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DISCO-RLS Trial is a randomized controlled trial to determine whether or not a fixed,
      low-dose therapy with ropinirole and/or gabapentin is safe and effective compared to either
      alone or placebo for the treatment of Restless Legs Syndrome in patients with End Stage Renal
      Disease receiving hemodialysis. DISCO-RLS will randomize a total of 80 participants.
      Participants will be randomized to 1 of 8 treatment sequences. Each sequence is composed of 4
      periods and in each period participants will receive 1 of 4 possible combinations of study
      medications (gabapentin+ropinirole, gabapentin+placebo ropinirole, ropinirole+placebo
      gabapentin, placebo gabapentin+placebo ropinirole). Eligible participants will complete a
      1-week Run-In period followed by 4 periods of 4 weeks each for a total of 16-week follow-up
      after randomization. A final study visit will be completed at the end of the 16 week
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly allocated to 1 of 8 treatment sequences. Each sequence is composed of 4 periods and in each period participants will receive 1 of 4 possible combinations of study medications (gabapentin+ropinirole, gabapentin+placebo ropinirole, ropinirole+placebo gabapentin, placebo gabapentin+placebo ropinirole).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study interventions will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>International Restless Legs Syndrome Study Group Rating Scale (IRLS)</measure>
    <time_frame>18 weeks (Baseline, Run-In, Follow-up)</time_frame>
    <description>The IRLS is a measure of severity of Restless Legs Syndrome. It includes 10 items, measured on a scale of 0-4. A score of 1-10 indicates mild severity, 11-20 indicates moderate severity, 21-30 is severe and 31-40 is very severe. Primary outcome is the difference in IRLS scores for each of the treatment regimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restless Legs Syndrome-6 Scale (RLS-6)</measure>
    <time_frame>18 weeks (Baseline, Run-In, Follow-up)</time_frame>
    <description>The RLS-6 is a measure of severity of Restless Legs Syndrome for the past week. It includes 6 items, measured on a scale of 0-10. Each item is measured from no symptoms (score of 0) to very severe symptoms (score of 10). Secondary outcome is the difference in RLS-6 scores for each of the treatment regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impressions (PGI)</measure>
    <time_frame>18 weeks (Baseline, Run-In, Follow-up)</time_frame>
    <description>The PGI is a measure of Restless Legs Syndrome symptom severity. It includes 1 item, measured on a scale of 1-7. 1 indicates mild severity, 3 indicates moderate severity, 5 is severe and 7 is very severe. Secondary outcome is the difference in PGI scores for each of the treatment regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro-Quality of Life Scale (EQ-5D-5L)</measure>
    <time_frame>18 weeks (Baseline, Run-In, Follow-up)</time_frame>
    <description>The EQ-5D-5L is a measure of health status. It includes 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale of 0-100 (0 being worst health and 100 being best health). The scale is measured by levels. Level 1 indicating no problems, 2 indicating slight problems, 3 indicating moderate problems, 4 indicating severe problems and 5 indicating extreme problems. Secondary outcome is the difference in EQ-5D-5L scores for each of the treatment regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of falls, fractures and hospitalizations/emergency room visits due to altered level of consciousness.</measure>
    <time_frame>18 weeks (Baseline, Run-In, Follow-up)</time_frame>
    <description>The total number of falls, fractures, or hospitalization/emergency rooms visits due to confusion/delirium or altered mental state.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>Gabapentin + Ropinirole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin + Placebo Ropinirole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropinirole + Placebo Gabapentin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Gabapentin + Placebo Ropinirole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>100 mg capsule</description>
    <arm_group_label>Gabapentin + Placebo Ropinirole</arm_group_label>
    <arm_group_label>Gabapentin + Ropinirole</arm_group_label>
    <other_name>GD-Gabapentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole</intervention_name>
    <description>0.50 mg capsule</description>
    <arm_group_label>Gabapentin + Ropinirole</arm_group_label>
    <arm_group_label>Ropinirole + Placebo Gabapentin</arm_group_label>
    <other_name>pms-Ropinirole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Gabapentin</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo Gabapentin + Placebo Ropinirole</arm_group_label>
    <arm_group_label>Ropinirole + Placebo Gabapentin</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ropinirole</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Gabapentin + Placebo Ropinirole</arm_group_label>
    <arm_group_label>Placebo Gabapentin + Placebo Ropinirole</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater or equal to 18 years

          -  Has received at least 90 days of in-center hemodialysis at a frequency at least 3
             times weekly

          -  RLS defined by 2012 Revised International Restless Legs Syndrome Study Group (IRLSSG)
             Diagnostic Criteria for RLS and of moderate severity defined by an IRLS score greater
             or equal to 10 with symptoms more than 2 days per week (see IRLS question #7)

          -  Provides informed consent

        Exclusion Criteria:

          -  Hemoglobin&lt;80g/L in the previous 4 weeks

          -  Intolerance to a dopamine agonists (e.g. pramipexole or ropinirole) or alpha 2 delta
             ligands (e.g. gabapentin, Neurontin, pregabalin, or Lyrica)

          -  Change in medication to treat RLS in previous 4 weeks

          -  Current pregnancy

          -  Planned kidney transplantation, travel or relocation in the next 6 months

          -  Unable to complete RLS symptom and HRQOL measurements due to language barrier or
             cognitive impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Michael Walsh, PhD,FRCPC(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute, McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kayla Pohl, BA, CCRP</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40694</phone_ext>
    <email>kayla.pohl@phri.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nova Scotia Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Karthik Tennankore</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hamilton Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Christian Rabbat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Deborah Zimmerman</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

